Janssen's Incivo offers mixed bag of benefits, says IQWiG
This article was originally published in Scrip
Janssen-Cilag's novel hepatitis C protease inhibitor, Incivo (telaprevir), in combination with peginterferon alfa and ribavirin, potentially offers a “hint” of added benefit for some patients, and more certain benefits for others over current standard therapy (peginterferon alfa and ribavirin), says IQWiG, the German HTA institute. However, it claims that the extent of those benefits is unquantifiable, largely because it does not view sustained virological response (SVR) as a formal patient outcome.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.